Zymeworks Inc. Common Stock (ZYME) - Total Liabilities

Latest as of September 2025: $77.20 Million USD

Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has total liabilities worth $77.20 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ZYME cash generation efficiency to assess how effectively this company generates cash.

Zymeworks Inc. Common Stock - Total Liabilities Trend (2014–2024)

This chart illustrates how Zymeworks Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check Zymeworks Inc. Common Stock (ZYME) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Zymeworks Inc. Common Stock Competitors by Total Liabilities

The table below lists competitors of Zymeworks Inc. Common Stock ranked by their total liabilities.

Company	Country	Total Liabilities
FMC Corporation NYSE:FMC	USA	$7.59 Billion
Ls Cable & System Asia Ltd KO:229640	Korea	₩246.52 Billion
Formula Systems (1985) Ltd F:FSY	Germany	€1.81 Billion
Hunan Valin Wire & Cable Co Ltd SHE:001208	China	CN¥3.23 Billion
Globant SA NYSE:GLOB	USA	$1.10 Billion
GRAIL, LLC NASDAQ:GRAL	USA	$344.15 Million
Beijing Yuanliu Hongyuan Electronic Technology Co Ltd SHG:603267	China	CN¥1.02 Billion
Zhejiang Runtu Co Ltd SHE:002440	China	CN¥1.76 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Zymeworks Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zymeworks Inc. Common Stock stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	6.94	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.24	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.19	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Zymeworks Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Zymeworks Inc. Common Stock (2014–2024)

The table below shows the annual total liabilities of Zymeworks Inc. Common Stock from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	$124.32 Million	+7.11%
2023-12-31	$116.07 Million	-25.48%
2022-12-31	$155.77 Million	+11.23%
2021-12-31	$140.04 Million	+9.02%
2020-12-31	$128.45 Million	+4.84%
2019-12-31	$122.52 Million	+91.82%
2018-12-31	$63.87 Million	+311.37%
2017-12-31	$15.53 Million	-81.73%
2016-12-31	$84.99 Million	+1631.02%
2015-12-31	$4.91 Million	-54.97%
2014-12-31	$10.90 Million	--

About Zymeworks Inc. Common Stock

NASDAQ:ZYME USA Biotechnology

Market Cap

$1.99 Billion

Market Cap Rank

#6694 Global

#1962 in USA

Share Price

$26.61

Change (1 day)

-3.38%

52-Week Range

$11.22 - $28.56

All Time High

$56.81